Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Heron Therapeutics (HRTX) Other Gross PP&E Adjustments (2016 - 2025)

Heron Therapeutics' Other Gross PP&E Adjustments history spans 13 years, with the latest figure at $19.6 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments fell 10.92% year-over-year to $19.6 million; the TTM value through Dec 2025 reached $19.6 million, down 10.92%, while the annual FY2025 figure was $19.6 million, 10.92% down from the prior year.
  • Other Gross PP&E Adjustments reached $19.6 million in Q4 2025 per HRTX's latest filing, up from -$708000.0 in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $22.0 million in Q4 2024 to a low of -$15.6 million in Q1 2021.
  • Average Other Gross PP&E Adjustments over 5 years is -$3.4 million, with a median of -$5.4 million recorded in 2023.
  • Peak YoY movement for Other Gross PP&E Adjustments: soared 1822.64% in 2023, then decreased 10.92% in 2025.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$12.1 million in 2021, then soared by 95.18% to -$583000.0 in 2022, then skyrocketed by 1822.64% to $10.0 million in 2023, then surged by 119.06% to $22.0 million in 2024, then dropped by 10.92% to $19.6 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Other Gross PP&E Adjustments are $19.6 million (Q4 2025), -$708000.0 (Q3 2025), and -$1.4 million (Q2 2025).